Recruiting

Observational Study

Sponsor:

Novartis Pharmaceuticals

Code:

NCT07677254

Conditions

Prostatic Neoplasms, Castration-Resistant

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Conditions

Prostatic Neoplasms, Castration-Resistant

Study ID

NCT07677254

Start date

Jun 30, 2026

Status verified date

Jul, 2026

Completion date

Nov 30, 2026

Anticipated

Primary completion date

Nov 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion criteria:

  • Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
  • Male sex at index, where index is the date of initial mCRPC diagnosis.
  • Age 18 years at index.

Exclusion criteria:

• None

Study Design

Enrollment

17111 participants

Anticipated

Interventions and Outcome Measures

Arms

mCRPC Cohort

Adult male patients with a recent diagnosis of mCRPC in PRECISION.

Primary outcome measure

  • Number of Patients by Prior Therapies [ Time Frame: Baseline ]
  • Number of Patients by Number of Post-index Lines of Therapy (LOTs) [ Time Frame: Up to approximately 5 years ]
  • Number of Patients by Type of Therapy at Each LOT [ Time Frame: Up to approximately 5 years ]
  • Percentage of Patients Switching From One Type of Therapy to Another at Each LOT [ Time Frame: Up to approximately 5 years ]
  • Time to First-line (1L) Treatment Initiation (TTTI) [ Time Frame: Up to approximately 5 years ]
  • Time to Next Therapy (TTNT) for Each LOT [ Time Frame: Up to approximately 5 years ]

Central Contacts and Locations

Central contacts

Novartis Pharmaceuticals

+41613241111novartis.email@novartis.com

Locations

Novartis

Recruiting

East Hanover, New Jersey, United States, 07936

More Information

Sponsor

Novartis Pharmaceuticals

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • Androgen Pathway Modulation-Resistant
  • APMR

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-07-16.